Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Trial to Evaluate COTI-2 in Combination with Eribulin in the Second or Subsequent Line Therapy of Patients with Triple Negative Metastatic Breast Cancer

Trial Profile

A Phase I Trial to Evaluate COTI-2 in Combination with Eribulin in the Second or Subsequent Line Therapy of Patients with Triple Negative Metastatic Breast Cancer

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 22 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs COTI 2 (Primary) ; Eribulin (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 22 May 2019 According to a Cotinga Pharmaceuticals media release, the company intends to use the proceeds from the latest offering to fund the initiation of this trial (triple negative breast cancer, COTI-2 in combination with eribulin).
    • 05 Nov 2018 According to a Cotinga Pharmaceuticals media release, the company has entered into a research collaboration with St. Vincent's University Hospital in Dublin, Ireland to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer.
    • 09 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top